Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01794741 · ClinicalTrials.gov registry record · Phase 3

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

A Phase 3 study of Allergic Rhinitis, sponsored by Meda Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
405
Enrollment target
20
Study locations

NCT01794741: Completed Phase 3 study of Allergic Rhinitis, sponsored by Meda Pharmaceuticals.

NCT01794741 is a Phase 3 study of Allergic Rhinitis that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 405 participants, above the 88-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (360% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01794741, a Phase 3 study of Allergic Rhinitis, has completed, sponsored by Meda Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
405 participants
Enrollment target
20
Study locations

Study Summary

This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis

Primary Outcome

reports of treatment emergent adverse events

Conditions Studied

Interventions

  • DRUG Dymista Nasal Spray
  • DRUG Fluticasone propionate nasal spray

Study Locations (20)

California

  • West Coast Clinical Trials - Costa Mesa
  • Allergy & Asthma Care Center of So. Cal - Long Beach
  • Southern California Research - Mission Viejo
  • Allergy Associates Medical Group Inc - San Diego
  • Allergy & Asthma Associates of Santa Clara Valley Research Cntr - San Jose

Colorado

  • Storms Clinical Research Institute - Colorado Springs
  • Colorado Allergy and Asthma Centers, PC - Denver
  • Asthma and Allergy Associates, PC - Pueblo

Missouri

  • The Clinical Research Center - St Louis
  • Clinical Research of the Ozarks,Inc - Warrensburg

Alabama

  • Clinical Research Center of Alabama,LLC - Birmingham

Alaska

  • Little Rock Allergy and Asthma Clinical research Center - Little Rock

Florida

  • Allergy and Asthma Care of Florida - Ocala

Georgia

  • Atlanta Allergy and Asthma Clinic - Stockbridge

Idaho

  • Idaho Allergy - Eagle

Trial Details

FieldValue
Enrollment Target 405 participants
Start Date 2013-02
Phase Phase 3
Meda Pharmaceuticals

19 total trials

What the finished NCT01794741 record still lists

NCT01794741 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (360% higher).

The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Dymista Nasal Spray is the first listed.

NCT01794741 names 20 study sites across 13 states, led by California, Colorado, Missouri.

Frequently Asked Questions

What is clinical trial NCT01794741 about?

NCT01794741 is a clinical study titled "3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis". This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis

What is the current status of trial NCT01794741?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2013-02.

What conditions does trial NCT01794741 study?

This clinical trial studies the following conditions: Allergic Rhinitis.

What interventions are being tested in trial NCT01794741?

The interventions under investigation include: Dymista Nasal Spray (DRUG), Fluticasone propionate nasal spray (DRUG).

Who is sponsoring clinical trial NCT01794741?

This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01794741 being conducted?

This trial has 20 study locations across Alabama, Alaska, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Allergic Rhinitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01794741's enrollment target sits among peer trials

405 2nd of 23 the highest of 23 other Allergic Rhinitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05576350 · 405 participants · NA

    TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

  • NCT07066657 · 405 participants · Phase 1

    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  • NCT06223360 · 406 participants · Phase 2

    A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

  • NCT06411769 · 406 participants · NA

    Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01794741, the US trial registry maintained by the National Library of Medicine. NCT01794741 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.